BACKGROUND: The expression of the scavenger receptor for advanced glycation end products (RAGE) and various ligands of RAGE correlate significantly with cancer progression. However, the mechanism of RAGE/sRAGE-induced cancer cell activation and ligand usage remain largely unknown. METHODS: Androgen-independent, highly invasive, as well as androgen-dependent, non-invasive human prostate carcinoma (CaP) cells were investigated for their interaction with the soluble form of RAGE (sRAGE). Using neutralizing antibodies and soluble proteins, the ligand for RAGE was identified on CaP cells and ligand binding with sRAGE was biochemically characterized. RESULTS: Both androgen-independent, highly invasive and androgen-dependent, non-invasive CaP cells interacted with immobilized sRAGE in a surprisingly strong manner. Using C-terminal truncation variants of RAGE we identified the V domain being responsible for the adhesion of CaP cells to sRAGE. Moreover, we demonstrate that this adhesion cannot be blocked by S100B or neutralizing antibodies against beta integrins, or amphoterin. However, the CaP cell-RAGE interaction was inhibited with either AGE-modified proteins, or with neutralizing antibodies against AGE or RAGE. Despite similar binding kinetics between AGE-modified BSA and different RAGE domains, only applying an excess of sRAGE, but not the VC1 or V domain of RAGE, was able to block the CaP cell-RAGE interaction. CONCLUSIONS: We identified AGEs as the ligand for RAGE on both invasive and non-invasive prostate cancer cells. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: The expression of the scavenger receptor for advanced glycation end products (RAGE) and various ligands of RAGE correlate significantly with cancer progression. However, the mechanism of RAGE/sRAGE-induced cancer cell activation and ligand usage remain largely unknown. METHODS: Androgen-independent, highly invasive, as well as androgen-dependent, non-invasive humanprostate carcinoma (CaP) cells were investigated for their interaction with the soluble form of RAGE (sRAGE). Using neutralizing antibodies and soluble proteins, the ligand for RAGE was identified on CaP cells and ligand binding with sRAGE was biochemically characterized. RESULTS: Both androgen-independent, highly invasive and androgen-dependent, non-invasive CaP cells interacted with immobilized sRAGE in a surprisingly strong manner. Using C-terminal truncation variants of RAGE we identified the V domain being responsible for the adhesion of CaP cells to sRAGE. Moreover, we demonstrate that this adhesion cannot be blocked by S100B or neutralizing antibodies against beta integrins, or amphoterin. However, the CaP cell-RAGE interaction was inhibited with either AGE-modified proteins, or with neutralizing antibodies against AGE or RAGE. Despite similar binding kinetics between AGE-modified BSA and different RAGE domains, only applying an excess of sRAGE, but not the VC1 or V domain of RAGE, was able to block the CaP cell-RAGE interaction. CONCLUSIONS: We identified AGEs as the ligand for RAGE on both invasive and non-invasive prostate cancer cells. (c) 2008 Wiley-Liss, Inc.
Authors: Michael Koch; Seth Chitayat; Brian M Dattilo; Andre Schiefner; Joachim Diez; Walter J Chazin; Günter Fritz Journal: Structure Date: 2010-10-13 Impact factor: 5.006
Authors: T Kwak; K Drews-Elger; A Ergonul; P C Miller; A Braley; G H Hwang; D Zhao; A Besser; Y Yamamoto; H Yamamoto; D El-Ashry; J M Slingerland; M E Lippman; B I Hudson Journal: Oncogene Date: 2016-09-26 Impact factor: 9.867
Authors: Dion Foster; Laura Spruill; Katherine R Walter; Lourdes M Nogueira; Hleb Fedarovich; Ryan Y Turner; Mahtabuddin Ahmed; Judith D Salley; Marvella E Ford; Victoria J Findlay; David P Turner Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-22 Impact factor: 4.254
Authors: Hifzur R Siddique; Vaqar M Adhami; Aijaz Parray; Jeremy J Johnson; Imtiaz A Siddiqui; Mohammad T Shekhani; Imtiyaz Murtaza; Noona Ambartsumian; Badrinath R Konety; Hasan Mukhtar; Mohammad Saleem Journal: Genes Cancer Date: 2013-05